N/A
93.396
To provide fundamental information on the cause and nature of cancer in people, with the expectation that this will result in better methods of prevention, detection and diagnosis, and treatment of neoplastic diseases. Cancer Biology Research includes the following research programs: cancer cell biology; cancer immunology, hematology and etiology; DNA and chromosomal aberrations; tumor biology and metastasis; and structural biology and molecular applications.
This chart shows obligations for the program by fiscal year. All data for this chart was provided by the
administering agency and sourced from SAM.gov, USASpending.gov, and Treasury.gov.
For more information on each of these data sources, please see the
About the data page.
It is estimated that 1,387 total awards will be made in FY2016. In FY2016, 340 competing RPG awards were made, which were 11.3% of the applications received. In FY2016, 10 competing SBIT/STTR awards were made, which were 7.4% of the applications received.
In FY2017, the estimated total awards to be made are 324.
In FY2018, the estimated total awards to be made are 320.
In FY2019, the actual total awards made were 371.
In FY2020, the actual total awards made was 422.
In FY2021, total awards made were 397.
In FY2022, the actual total awards made were 383.
In FY2023, the actual total awards made were 390.
In FY2024, the estimated total awards to be made are 1,846.
In FY2025, the estimated total awards to be made are 2,041.
Single Audit Applies (2 CFR Part 200 Subpart F):
For additional information on single audit requirements for this program, review the current Compliance Supplement.
OMB is working with the U.S. Government Accountability Office (GAO) and agency offices of inspectors general to include links to relevant oversight reports. This section will be updated once this information is made available.